Loading stock data…
Cibus (CBUS)
$1.61+0.02 (+1.26%)
Market ClosedLast close Sep 8
Cibus, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cibus, Inc. in the Healthcare sector is trading at $1.61 with a market capitalization of $104M. Wall Street consensus targets $14.33 (3 analysts), implying a +790.3% move over the next 12 months. The stock is currently near its 52-week low of $1.09, remaining 14.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +790.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.68M↑ | $1.06M↑ | $615,000↓ | $933,000↓ | $1.03M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$12.12M↑ | -$13.46M↑ | -$15.44M↑ | -$17.95M↑ | -$20.62M |
| Net Income | -$21.22M↑ | -$31.29M↓ | -$23.54M↑ | -$25.37M↑ | -$46.89M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$104.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-285.85%
Volume
Today's trading volume
70,891
Recent News
Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Quarterly Update Report
Download the Complete Report Here Cibus, Inc. (CBUS) Interoc Expands Rice Pipeline to Five Traits; Platform Revenue and Cost Discipline Advance as LATAM Launch Moves to 2028 Key Takeaways: Rice commercialization advanced as Interoc testing began and the relationship expanded from two to five traits, although initial LATAM launch timing moved to 2028. Sustainable Ingredients […] The post Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Quarterly Update Report appeared first
Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Downloadable Quarterly Update Report
Cibus, Inc. (CBUS) Interoc Expands Rice Pipeline to Five Traits; Platform Revenue and Cost Discipline Advance as LATAM Launch Moves to 2028 Read Exec Edge’s Initiation on Cibus, Inc. Here Subscribe to our Weekly Newsletter to Receive All Research Contact: Executives-Edge.com karenr@capmarketsmedia.com The post Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Downloadable Quarterly Update Report appeared first on ExecEdge.
Cibus, Inc. Q2 2026 Earnings Call Summary
Moby summary of Cibus, Inc.'s Q2 2026 earnings call
Cibus Inc (CBUS) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Trait Pipeline Model ...
Despite a delayed rice launch and cash runway concerns, Cibus expands partnerships and advances regulatory approvals across key markets.
Cibus Q2 Earnings Call Highlights
Cibus (NASDAQ:CBUS) reported second-quarter 2026 revenue of $1.0 million, compared with $0.9 million a year earlier, as the agricultural biotechnology company advanced its Sustainable Ingredients program and updated the expected timing of its initial rice launch in Latin America. For the first six